NASDAQ: INBXInhibrx Inc Stock
$34.70+0.21 (+0.61%)
Updated May 17, 2024
INBX Price
$34.70
Fair Value Price
$1.31
Market Cap
$1.82B
52 Week Low
$14.31
52 Week High
$39.79
P/E
-6.38x
P/B
157.19x
P/S
1,069.66x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.78M
Earnings
-$271.16M
Gross Margin
100%
Operating Margin
-13,390.07%
Profit Margin
-15,207.8%
Debt to Equity
23.95
Operating Cash Flow
-$216M
Beta
1.7
Next Earnings
May 24, 2024
Ex-Dividend
N/A
Next Dividend
N/A
INBX Overview
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how INBX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
INBX ($34.70) is overvalued by 2,548.97% relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
INBX ($34.70) is not significantly undervalued (2,548.97%) relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
INBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more INBX due diligence checks available for Premium users.
Be the first to know about important INBX news, forecast changes, insider trades & much more!
INBX News
Valuation
INBX fair value
Fair Value of INBX stock based on Discounted Cash Flow (DCF)
Price
$34.70
Fair Value
$1.31
Overvalued by
2,548.97%
INBX ($34.70) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
INBX ($34.70) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
INBX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
INBX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.38x
Industry
8.47x
Market
30.97x
INBX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
157.19x
Industry
6.01x
INBX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
INBX's financial health
Profit margin
Revenue
$0.0
Net Income
-$78.7M
Profit Margin
0%
INBX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
INBX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$288.6M
Liabilities
$277.0M
Debt to equity
23.95
INBX's short-term assets ($274.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
INBX's short-term assets ($274.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
INBX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$63.1M
Investing
-$1.1M
Financing
$38.7M
INBX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
INBX vs Biotech Stocks
Inhibrx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.